SK287335B6 - Použitie 4-{(4-metylpiperazin-1-ylmetyl)-N-[4-metyl-3-(4-pyrid-3- yl)pyrimidin-2-ylamino]fenyl}-benzamidu na prípravu farmaceutických kompozícií na liečenie gastrointestinálnych strómových tumorov - Google Patents

Použitie 4-{(4-metylpiperazin-1-ylmetyl)-N-[4-metyl-3-(4-pyrid-3- yl)pyrimidin-2-ylamino]fenyl}-benzamidu na prípravu farmaceutických kompozícií na liečenie gastrointestinálnych strómových tumorov Download PDF

Info

Publication number
SK287335B6
SK287335B6 SK518-2003A SK5182003A SK287335B6 SK 287335 B6 SK287335 B6 SK 287335B6 SK 5182003 A SK5182003 A SK 5182003A SK 287335 B6 SK287335 B6 SK 287335B6
Authority
SK
Slovakia
Prior art keywords
treatment
formula
salt
methyl
pyrimidin
Prior art date
Application number
SK518-2003A
Other languages
English (en)
Slovak (sk)
Other versions
SK5182003A3 (en
Inventor
Elisabeth Buchdunger
Renaud Capdeville
George Daniel Demetri
Sasa Dimitrijevic
Brian J. Druker
Jonathan A. Fletcher
Heikki Joensuu
Sandra Leta Silberman
David Tuveson
Michael C. Heinrich
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22920224&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK287335(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SK5182003A3 publication Critical patent/SK5182003A3/sk
Publication of SK287335B6 publication Critical patent/SK287335B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK518-2003A 2000-10-27 2001-10-26 Použitie 4-{(4-metylpiperazin-1-ylmetyl)-N-[4-metyl-3-(4-pyrid-3- yl)pyrimidin-2-ylamino]fenyl}-benzamidu na prípravu farmaceutických kompozícií na liečenie gastrointestinálnych strómových tumorov SK287335B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24381000P 2000-10-27 2000-10-27
PCT/EP2001/012442 WO2002034727A2 (en) 2000-10-27 2001-10-26 Treatment of gastrointestinal stromal tumors

Publications (2)

Publication Number Publication Date
SK5182003A3 SK5182003A3 (en) 2004-02-03
SK287335B6 true SK287335B6 (sk) 2010-07-07

Family

ID=22920224

Family Applications (1)

Application Number Title Priority Date Filing Date
SK518-2003A SK287335B6 (sk) 2000-10-27 2001-10-26 Použitie 4-{(4-metylpiperazin-1-ylmetyl)-N-[4-metyl-3-(4-pyrid-3- yl)pyrimidin-2-ylamino]fenyl}-benzamidu na prípravu farmaceutických kompozícií na liečenie gastrointestinálnych strómových tumorov

Country Status (26)

Country Link
US (1) US6958335B2 (zh)
EP (1) EP1332137B1 (zh)
JP (1) JP4386635B2 (zh)
KR (1) KR100885129B1 (zh)
CN (1) CN1276754C (zh)
AT (1) ATE321556T1 (zh)
AU (2) AU2002218262B2 (zh)
BR (1) BRPI0114870B8 (zh)
CA (1) CA2424470C (zh)
CY (1) CY1105055T1 (zh)
CZ (1) CZ303944B6 (zh)
DE (1) DE60118430T2 (zh)
DK (1) DK1332137T3 (zh)
ES (1) ES2260317T3 (zh)
HK (1) HK1058193A1 (zh)
HU (1) HU229106B1 (zh)
IL (2) IL155029A0 (zh)
MX (1) MXPA03003703A (zh)
NO (1) NO324948B1 (zh)
NZ (1) NZ525254A (zh)
PL (1) PL209733B1 (zh)
PT (1) PT1332137E (zh)
RU (1) RU2301066C2 (zh)
SK (1) SK287335B6 (zh)
WO (1) WO2002034727A2 (zh)
ZA (1) ZA200302155B (zh)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ299756B6 (cs) * 2001-05-16 2008-11-12 Novartis Ag Kombinace s obsahem N-{5-[4-(4-methyl-piperazino-methyl)benzoylamido]-2-methylfenyl}-4-(3-pyridyl)-2-pyrimidin-aminu k lécení proliferativních onemocnení
DE60216281T2 (de) * 2001-06-29 2007-07-05 Ab Science Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen
US7727731B2 (en) * 2001-06-29 2010-06-01 Ab Science Potent, selective and non toxic c-kit inhibitors
WO2003002108A2 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory diseases
CA2452392A1 (en) * 2001-06-29 2003-01-16 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd)
CA2452366A1 (en) * 2001-06-29 2003-01-16 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
US20040242612A1 (en) * 2001-09-20 2004-12-02 Alain Moussy Use of tyrosine kinase inhibitors for promoting hair growth
EP1427379B1 (en) * 2001-09-20 2008-08-13 AB Science Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
CA2477111A1 (en) * 2002-02-27 2003-09-04 Ab Science Use of tyrosine kinase inhibitors for treating cns disorders
FR2844452A1 (fr) * 2002-09-18 2004-03-19 Inst Gustave Roussy Igr Utilisation d'inhibiteurs specifiques de tyrosine kinases pour l'immunomodulation
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
CA2538523A1 (en) * 2003-09-19 2005-03-31 Novartis Ag Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
WO2007089716A2 (en) * 2006-02-01 2007-08-09 The Regents Of The University Of California Use of aminopyrimidine compounds in the treatment of immune disorders
EP2061468A4 (en) * 2006-09-11 2011-05-04 Curis Inc TYROSINE KINASE INHIBITORS CONTAINING ZINC BINDING CHARACTERISTIC GROUP
US20080221132A1 (en) * 2006-09-11 2008-09-11 Xiong Cai Multi-Functional Small Molecules as Anti-Proliferative Agents
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US20090082361A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched imatinib
CN101584696A (zh) 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
US8530492B2 (en) 2009-04-17 2013-09-10 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
KR102061743B1 (ko) 2011-03-04 2020-01-03 뉴젠 세러퓨틱스 인코포레이티드 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
WO2012155339A1 (zh) 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
US20160015708A1 (en) 2012-02-21 2016-01-21 Ranbaxy Laboratories Limited Stable dosage forms of imatinib mesylate
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
JP6464084B2 (ja) 2012-07-27 2019-02-06 イズミ テクノロジー，エルエルシー 排出阻害剤およびこれを用いる治療法
AU2014296032A1 (en) 2013-07-31 2016-03-17 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
WO2019016673A2 (en) 2017-07-20 2019-01-24 Kashiv Pharma Llc STABLE PHARMACEUTICAL COMPOSITION OF ORAL ADMINISTRATION OF IMATINIB
SG11202007198WA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of gastrointestinal stromal tumors
US20220354951A1 (en) 2019-08-02 2022-11-10 Onehealthcompany, Inc. Treatment of Canine Cancers
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
BR112022002609A2 (pt) 2019-08-12 2022-08-09 Deciphera Pharmaceuticals Llc Métodos de tratamento de tumores estromais gastrointestinais
KR20220123058A (ko) 2019-12-30 2022-09-05 데시페라 파마슈티칼스, 엘엘씨. 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의 조성물
DK4084778T3 (da) 2019-12-30 2023-12-11 Deciphera Pharmaceuticals Llc Amorfe kinaseinhibitorformuleringer og fremgangsmåder til anvendelse deraf
KR102535840B1 (ko) 2020-07-31 2023-05-23 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물의 위장관기질종양 예방, 개선 또는 치료 용도
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (zh) * 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
JP2002523455A (ja) * 1998-08-31 2002-07-30 スージェン・インコーポレーテッド 蛋白質キナーゼ活性の調節剤としての幾何学的に制限された２−インドリノン誘導体

Also Published As

Publication number Publication date
ATE321556T1 (de) 2006-04-15
RU2301066C2 (ru) 2007-06-20
NO324948B1 (no) 2008-01-07
PL362148A1 (en) 2004-10-18
KR20030051656A (ko) 2003-06-25
NO20031833D0 (no) 2003-04-24
WO2002034727A3 (en) 2003-03-27
ES2260317T3 (es) 2006-11-01
KR100885129B1 (ko) 2009-02-23
BRPI0114870B8 (pt) 2021-05-25
CA2424470A1 (en) 2002-05-02
JP4386635B2 (ja) 2009-12-16
CZ303944B6 (cs) 2013-07-10
ZA200302155B (en) 2004-04-22
BRPI0114870B1 (pt) 2020-06-16
HK1058193A1 (en) 2004-05-07
IL155029A (en) 2009-09-22
DE60118430T2 (de) 2006-10-26
PL209733B1 (pl) 2011-10-31
SK5182003A3 (en) 2004-02-03
CN1622808A (zh) 2005-06-01
EP1332137A2 (en) 2003-08-06
CN1276754C (zh) 2006-09-27
CZ20031152A3 (en) 2004-04-14
NZ525254A (en) 2006-02-24
PT1332137E (pt) 2006-07-31
US6958335B2 (en) 2005-10-25
WO2002034727A2 (en) 2002-05-02
BR0114870A (pt) 2004-02-17
IL155029A0 (en) 2003-10-31
CY1105055T1 (el) 2010-03-03
US20040023976A1 (en) 2004-02-05
JP2004512328A (ja) 2004-04-22
DE60118430D1 (de) 2006-05-18
MXPA03003703A (es) 2005-01-25
NO20031833L (no) 2003-04-24
CA2424470C (en) 2009-06-09
AU2002218262B2 (en) 2005-09-29
HUP0301512A2 (hu) 2003-11-28
DK1332137T3 (da) 2006-07-17
HU229106B1 (en) 2013-07-29
AU1826202A (en) 2002-05-06
EP1332137B1 (en) 2006-03-29

Similar Documents

Publication Publication Date Title
SK287335B6 (sk) Použitie 4-{(4-metylpiperazin-1-ylmetyl)-N-[4-metyl-3-(4-pyrid-3- yl)pyrimidin-2-ylamino]fenyl}-benzamidu na prípravu farmaceutických kompozícií na liečenie gastrointestinálnych strómových tumorov
AU2002218262A1 (en) Treatment of gastrointestinal stromal tumors
TWI670060B (zh) 醛化合物及其醫藥組成物及用途
JP2016529245A (ja) 固形腫瘍の処置方法
CN107072991A (zh) 磷酸酶抑制剂的人类给药
US11583536B2 (en) Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use
JP2023058582A (ja) 神経芽細胞腫の治療における使用のためのオーロラａキナーゼ阻害剤
AU2020284558A1 (en) Methods of treating cholangiocarcinoma
ES2934846T3 (es) Inhibidores de CDK para tratamiento de PAH
JP7333560B2 (ja) 放射線及び／又は化学療法の曝露に関連付けられる副作用を処置及び／又は防止する剤、組成物及びキット
US20190336621A1 (en) Radioactive compound for diagnosis of malignant melanoma and use thereof
SG172922A1 (en) Combination therapies for neoplastic disorders
KR20240141067A (ko) 표적 단백질 및 표적 분해 단백질에 결합하는 화합물, 이를 유효성분으로 함유하는 약학적 조성물, 및 이의 용도
CN118526503A (zh) 治疗或预防败血症或与败血症相关的病情的化合物
TW202423445A (zh) 英菲格拉替尼在治療胃癌和腺癌中的用途
CN117396202A (zh) 给药方案
EP1551408A1 (en) 4-(4-methylpiperazin-1-ylmethyl)-n- 4-pyridin-3-yl)pyrimidin -2-ylamino)phenyl -benzamide for treating anaplastic thyroid cancer

Legal Events

Date Code Title Description
PC4A Assignment and transfer of rights

Owner name: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., BOSTO, US

Free format text: FORMER OWNER: NOVARTIS AG, BASEL, CH

Effective date: 20130917

Owner name: OREGON HEALTH & SCIENCE UNIVERSITY, PORTLAND, , US

Free format text: FORMER OWNER: NOVARTIS AG, BASEL, CH

Effective date: 20130917

Owner name: NOVARTIS AG, BASEL, CH

Free format text: FORMER OWNER: NOVARTIS AG, BASEL, CH

Effective date: 20130917

Owner name: DANA-FARBER CANCER INSTITUTE INC., BOSTON, MA, US

Free format text: FORMER OWNER: NOVARTIS AG, BASEL, CH

Effective date: 20130917

QB4A Licence contract registered or granted

Free format text: NON-EXCLUSIVE LICENSE

Name of requester: NOVARTIS SLOVAKIA S.R.O., SK

Effective date: 20131031

MK4A Expiry of patent

Expiry date: 20211026